TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19621732
Drug: Triple-drug Hp
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-drug Hp eradication therapy (lansoprazole 30 mg bid, amoxicillin 1000 mg bid, clarithromycin 500 mg bid) for 2 weeks
Study: 11368983
Drug: Levonorgestrel (LNG)
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel (LNG) 0.75 mg administered twice immediately before ovulation
Study: 9412549
Drug: Inhaled albuterol
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled albuterol (800 micrograms/day)
Study: 7528360
Drug: Low-dose aprotinin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aprotinin (30,000 KIU/kg in the priming solution)
Study: 3293777
Drug: Vitamin supplements
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin supplements (400 mg each of ascorbic acid and alpha-tocopherol)
Study: 29072165
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care therapy for respiratory infection along with a single oral dose of 100,000 IU of vitamin D3
Study: 29072165
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care therapy alone
Study: 19737278
Drug: Super-selective intraprostatic
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Super-selective intraprostatic androgen deprivation therapy
Study: 17175104
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg rofecoxib (selective COX-2 inhibitor)
Study: 17175104
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg ketorolac (dual COX-1/COX-2 inhibitor)
Study: 14996144
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg daily for up to 8 weeks
Study: 7935234
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (TIVA) with midazolam and fentanyl
Study: 7935234
Drug: Inhalation anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation anesthesia with thiamylal, enflurane, and nitrous oxide
Study: 3341258
Drug: Full-fat acidified
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-fat acidified milk fortified with 15 mg of elemental Fe as ferrous sulfate and 100 mg of ascorbic acid/100 g of powder
Study: 28025964
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of pregabalin 150-mg capsules
Study: 28025964
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of pregabalin 150-mg capsules
Study: 23080548
Drug: Sequential clomiphene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential clomiphene citrate/hMG regimen (CC/hMG)
Study: 19271419
Drug: MgCl2 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: MgCl2 5% solution (450 mg elemental magnesium)
Study: 29132879
Drug: Rivaroxaban (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (2.5 mg orally twice a day) plus Aspirin (100 mg once a day)
Study: 29132879
Drug: Rivaroxaban (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (5 mg orally twice a day)
Study: 25845277
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg IV bolus at induction, followed by 0.25 mg/kg/h infusion until end of surgery)
Study: 24117389
Drug: Placebo (initially)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (initially) then Ustekinumab 45 mg or 90 mg
Study: 23561840
Drug: High-dose propofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose propofol (3.2 μg/mL)
Study: 23561840
Drug: Medium-dose propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medium-dose propofol (2.4 μg/mL)
Study: 23561840
Drug: Low-dose propofol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose propofol (1.8 μg/mL)
Study: 19092348
Drug: Celiac axis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiac axis infusion (CAI) and radiotherapy (RT) consisting of intra-arterial mitoxantrone, 5-FU, leucovorin, and cisplatinum in combination with 30 x 1.8 Gy radiotherapy (group A)
Study: 19092348
Drug: Celiac axis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiac axis infusion (CAI) and radiotherapy (RT) for periampullary tumors
Study: 19092348
Drug: Celiac axis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiac axis infusion (CAI) and radiotherapy (RT) for pancreatic cancer
Study: 12500073
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 or 40 mg)
Study: 12500073
Drug: Clomipramine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (75 or 150 mg)
Study: 11303310
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of trometamol (TRIS, pH = 10.5) intravenously for 5 minutes, followed by deep breathing for 5 minutes at a rate of 40/min.
Study: 8623998
Drug: Neostigmine 0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.06 mg.kg‐1
Study: 8623998
Drug: Butyrylcholinesterase (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butyrylcholinesterase (25 ml.kg‐1 and 70 ml.kg‐1 of human plasma equivalent)
Study: 3898847
Drug: Single preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single preoperative intramuscular dose of cefoxitin (2 gm)
Study: 3898847
Drug: Two or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two or three doses of cefoxitin (2 gm)
Study: 1675315
Drug: 150 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/day aspirin
Study: 6447272
Drug: Mega-doses of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mega-doses of vitamin E
Study: 24283222
Drug: First- and
Normalized name: hexylresorcinol
DrugBank: Hexylresorcinol (DB11254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First- and second-generation antipsychotics
Study: 21338276
Drug: Tetradecylthioacetic acid
Normalized name: Tetradecylthioacetic acid
DrugBank: Tetradecylthioacetic acid (DB18802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetradecylthioacetic acid (TTA) 1000 mg daily for 28 days
Study: 17519543
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) given orally
Study: 17519543
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) in vitro
Study: 9529766
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen treatment (100% oxygen, pressure)
Study: 31786934
Drug: Ketamine (0.71
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.71 mg/kg)
Study: 30918134
Drug: Exenatide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (10 μg b.i.d.) for 12 weeks
Study: 30918134
Drug: Metformin (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1,000 mg b.i.d.) for 12 weeks
Study: 23887741
Drug: Levosimendan infusion
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan infusion at 0.1 μg/kg/min, every 30 days
Study: 17121211
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg once a day
Study: 10694193
Drug: L-arginine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (15 g/day)
Study: 9017786
Drug: Pharmacologic agents
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic agents that reduce leukotriene activity or enhance prostaglandin activity, or agents that do both; specific agents not detailed.
Study: 9017786
Drug: Beta-agonists and
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-agonists and cromolyn sodium; specific dosages and durations not mentioned.
Study: 25100359
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone treatment for 36 months
Study: 10533793
Drug: Interferon-alpha (IFNalpha)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha (IFNalpha) treatment
Study: 29780293
Drug: Granulocyte-colony stimulating
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Granulocyte-colony stimulating factor (G-CSF) followed by infusion of autologous mobilized peripheral blood mononuclear cells (mPBMCs)
Study: 24655586
Drug: Hatha yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hatha yoga as add-on treatment
Study: 24655586
Drug: Cortisol improvers
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol improvers in week 1 of therapy
Study: 17546332
Drug: 200mg iron
Normalized name: polysaccharide iron complex 200 MG [EZFE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg iron sulfate alone (40 mg elemental iron) for 30 weeks
Study: 15705659
Drug: 1-(13)C-labeled l-leucine
Normalized name: L-Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-(13)C-labeled l-leucine infusion
Study: 10088595
Drug: Two treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two treatments
Study: 8848187
Drug: Bromocriptine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (15 mg daily)
Study: 1970108
Drug: Autolymphocyte therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autolymphocyte therapy (ALT) plus oral cimetidine
Study: 1970108
Drug: Autolymphocyte therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autolymphocyte therapy (ALT)
Study: 7425360
Drug: Methohexital 20
Normalized name: methohexital 200 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methohexital 20 mg/kg, rectally
Study: 7425360
Drug: Methohexital 25
Normalized name: Methohexital
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methohexital 25 mg/kg, rectally
Study: 7425360
Drug: Methohexital 30
Normalized name: Methohexital
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methohexital 30 mg/kg, rectally
Study: 7425360
Drug: Methohexital (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methohexital (all doses)
Study: 30309264
Drug: Insulin-like growth
Normalized name: Insulin-like growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-like growth factor binding protein-1 levels
Study: 24007304
Drug: Mavoglurant (AFQ056)
Normalized name: Mavoglurant
DrugBank: Mavoglurant (DB13004)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavoglurant (AFQ056) 25 mg bid to 100 mg bid
Study: 19571161
Drug: quercetin+vitamin C
Approvals — FDA: no, EMA: no, PMDA: no
Description: quercetin+vitamin C (166mg+133mg/capsule)
Study: 19571161
Drug: alpha‐lipoic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha‐lipoic acid (300mg/capsule)
Study: 17533206
Drug: Structured pharmacist
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured pharmacist medication history interview with assessment and generation of a postoperative medication order form
Study: 17533206
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (nurse‐conducted medication histories and surgeon‐generated medication orders)
Study: 11347834
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (Enoxaparin)
Study: 8255974
Drug: Isoprenaline infusion
Normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoprenaline infusion (0.5-3.0 micrograms/min)
Study: 8255974
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg atenolol (beta 1 antagonist)
Study: 8255974
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg nadolol (beta 1/beta 2 blocker)
Study: 8255974
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg nadolol (beta 1/beta 2 blocker)
Study: 3318433
Drug: Aspirin 900
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 900 mg four times daily
Study: 23190785
Drug: Control vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccines (MenC‐TT coadministered with DTPa‐HBV‐IPV/Hib)
Study: 12914871
Drug: Celecoxib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (100 to 400 mg twice daily)
Study: 31160249
Drug: Cediranib (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib (30 mg orally, once daily)
Study: 19709417
Drug: Oxaliplatin (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin (120 mg/m2, d1) + Dacarbazine (175 mg/m2, d13)
Study: 9692689
Drug: omeprazole 10
Normalized name: omeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole 10 mg o.m.
Study: 9692689
Drug: antacid/alginate liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: antacid/alginate liquid 10 mL q.d.s.
Study: 11465413
Drug: O/W emulsion-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: O/W emulsion-based cream for lidocaine
Study: 11465413
Drug: Both active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both active treatments (microemulsion and O/W emulsion)
Study: 9611474
Drug: Subgingival application
Normalized name: DOXYCYCLINE 10% SA SUBGINGIVAL SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgingival application of 25% metronidazole gel
Study: 9611474
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of scaling and metronidazole gel application
Study: 7834161
Drug: Caffeine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (2.5 mg.kg‐1 body weight)
Study: 7834161
Drug: Ethanol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (25 ml in 150 ml of grapefruit juice)
Study: 3202091
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A (3 mg RE or 10,000 IU daily for 4 months)
Study: 3202091
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily for 4 months)
Study: 29171002
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of carbamazepine and oxcarbazepine/phenytoin
Study: 23860530
Drug: Aprepitant (day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant (day 1, 125 mg; days 2 and 3, 80 mg) with dexamethasone (12 mg on day 1, 4 mg on days 2 and 3)
Study: 23860530
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with dexamethasone (20 mg on day 1, 8 mg on days 2 and 3)
Study: 23860530
Drug: Aprepitant (day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant (day 1, 125 mg; days 2 and 3, 80 mg)
Study: 19952817
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (NaHCO3) 0.3 g.kg body mass
Study: 19952817
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride (placebo; PL trial) 0.045 g.kg body mass
Study: 18639418
Drug: Endovenous laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovenous laser treatment
Study: 17026559
Drug: Colon preparation
Normalized name: porcine colon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colon preparation on the day of colonoscopy (on-the-day group)
Study: 17026559
Drug: Colon preparation
Normalized name: porcine colon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colon preparation the night before colonoscopy (previous night group)
Study: 12968982
Drug: Furosemide (F)
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide (F) 0.5 mg kg(‐1) intravenously
Study: 11469297
Drug: Aqueous calcium
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous calcium hydroxide suspension
Study: 18388097
Drug: Calcium dobesilate
Normalized name: CALCIUM DOBESILATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium dobesilate (500 mg every 8 hours for 49 days)
Study: 16024973
Drug: G/A or
Approvals — FDA: no, EMA: no, PMDA: no
Description: G/A or A/A genotypes
Study: 16024973
Drug: G/A and
Approvals — FDA: no, EMA: no, PMDA: no
Description: G/A and A/A patients
Study: 31246057
Drug: Emotion-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emotion-focused therapy for trauma
Study: 31246057
Drug: Increase in
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in primary adaptive emotions from early to late treatment sessions
Study: 26457986
Drug: Fludarabine (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine (not specified if alone or in combination)
Study: 26457986
Drug: Second-line therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line therapy that induces a complete remission (CR)
Study: 26457986
Drug: FC-based second-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: FC-based second-line therapy (including rituximab in 20%) or stem cell transplant
Study: 22158147
Drug: Vardenafil (VAR)
DrugBank: Vardenafil (DB00862)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vardenafil (VAR) 10 mg on demand
Study: 20332288
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment for chronic pain
Study: 18053943
Drug: Low dose,
Normalized name: Aspirin Low Dose, 81 mg oral tablet, chewable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose, 3 mg (Group A)
Study: 18053943
Drug: High dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose, 10 mg (Group B)
Study: 2960296
Drug: Hepatic artery
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic artery infusion (0.3 mg/kg/d continuous floxuridine infusion, alternating with saline solution every two weeks)
Study: 2960296
Drug: Portal vein
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Portal vein infusion (0.3 mg/kg/d continuous floxuridine infusion, alternating with saline solution every two weeks)
Study: 2960296
Drug: Crossover to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover to hepatic arterial infusion after portal vein infusion
Study: 21569996
Drug: Combination-therapy trastuzumab
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination-therapy trastuzumab plus docetaxel (H+D)
Study: 21569996
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy of single-agent trastuzumab followed by docetaxel (H→D)
Study: 21569996
Drug: Monotherapy trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy trastuzumab in H→D group
Study: 21569996
Drug: Retrospective analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrospective analysis of trastuzumab treatment beyond progression
Study: 11057795
Drug: Dopexamine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopexamine (both doses)
Study: 8399607
Drug: Intraperitoneal vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal vancomycin (1 g) and oral pefloxacin (400 mg b.i.d.)
Study: 8399607
Drug: Intraperitoneal vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal vancomycin (1 g) and gentamicin (80 mg loading dose, followed by 15 mg/2 L)
Study: 6576742
Drug: Wet aerosol
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Wet aerosol salbutamol (10 mg, 4 x 0.5 ml of 0.5% standard solution)
Study: 6576742
Drug: Metered dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered dose inhaler (MDI) salbutamol (800 micrograms, 8 x 100 micrograms)
Study: 31104629
Drug: Monetary incentive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monetary incentive of 2.00 for every maternal client attending postnatal care within 48 h of delivery (treatment group)
Study: 31104629
Drug: Monetary incentive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monetary incentive of 2.00 for every neonatal client attending postnatal care within 48 h of delivery (treatment group)
Study: 18070468
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg/d and aspirin 100 mg/d plus cilostazol 200 mg/d
Study: 18070468
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg/d and aspirin 100 mg/d
Study: 10988282
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg twice daily for 1 week, then 50 mg twice daily for 5 weeks)
Study: 10988282
Drug: Indomethacin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (75 mg daily) with Losartan
Study: 10988282
Drug: Indomethacin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (75 mg daily) with Captopril
Study: 8989058
Drug: Local anesthesia
Normalized name: Esters of benzoic acid for local anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthesia (subcutaneous anesthetic infiltration)
Study: 6739139
Drug: Apalcillin 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apalcillin 500 mg
Study: 6739139
Drug: Apalcillin 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apalcillin 1000 mg
Study: 6739139
Drug: Apalcillin 2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apalcillin 2000 mg
Study: 6739139
Drug: Apalcillin 3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apalcillin 3000 mg
Study: 6739139
Drug: Apalcillin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apalcillin (all doses)
Study: 31317029
Drug: Lycopene 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene 7 mg daily
Study: 31317029
Drug: Lycopene 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene 30 mg daily (formulation 1)
Study: 31317029
Drug: Lycopene 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene 30 mg daily (formulation 2)